technology

press releases

Date Title and Summary Additional Formats
Toggle Summary Top-line data from pivotal PROMISE 1 study of eptinezumab for migraine prevention on track to be announced 2Q 2017 Conference call set for 5 p.m. EDT today BOTHELL, Wash., April 27, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company View HTML
Toggle Summary - Eptinezumab rational design results in differentiated clinical profile for migraine prevention therapy - - Eptinezumab responders showed significant and sustained reduction in migraine days following a single infusion -   BOTHELL, Wash., April 24, 2017 (GLOBE NEWSWIRE) -- Alder View HTML
Toggle Summary BOTHELL, Wash., April 20, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals®, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will report its first quarter 2017 financial and operating results after the View HTML
Toggle Summary Former Merck Chief Marketing Officer, Experienced Director of Biopharma Companies Joins Alder Board as Company Moves Closer to First BLA Submission and Planned Commercialization View HTML
Toggle Summary BOTHELL, Wash., March 28, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the upcoming 16 th Annual Needham Healthcare Conference View HTML
Toggle Summary BOTHELL, Wash., March 06, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that data for eptinezumab (formerly ALD403), which is in clinical development for the prevention View HTML
Toggle Summary 2016 Clinical Data Support Eptinezumab's Potential to Deliver a Unique Combination of Speed to Clinical Benefit and Effectiveness That Persists for at Least Three Months After a Single Administration Top-Line Data from First Pivotal Phase 3 Study, PROMISE 1, On Track for First Half 2017 Conference View HTML
Toggle Summary BOTHELL, Wash., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will report its fourth quarter and full year 2016 financial and operating results View HTML
Toggle Summary BOTHELL, Wash., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the upcoming Leerink Partners 6th Annual Global Healthcare View HTML
Toggle Summary BOTHELL, Wash., Jan. 02, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the upcoming 35th Annual J.P. View HTML